Breathe Well Live Well
|
Glaxo's Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Yahoo News Several companies including Teva Pharmaceutical Industries Limited TEVA and AstraZeneca plc AZN are looking to bring their anti IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). |
View full post on asthma – Google News
BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News
|
SkyePharma asthma drug wins European backing
Reuters UK By Paul Sandle | LONDON (Reuters) – SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European … SkyePharma's asthma drug wins European backing |
View full post on asthma – Google News
|
SkyePharma's asthma drug wins European backing
Reuters UK LONDON (Reuters) – British pharmaceutical company SkyePharma said on Friday its asthma therapy Flutiform had been recommended for approval by European regulators, sending its shares soaring. Flutiform was referred to the European Medicines Agency (EMA) … |
View full post on asthma – Google News